Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects

Alimentary Pharmacology & Therapeutics
Andrea Lombardi, Mario U Mondelli

Abstract

Immune checkpoint inhibitors have revolutionised the oncological landscape in the last few years. Possible applications include the treatment of hepatocellular carcinoma and cholangiocarcinoma. Unfortunately, new immune-related adverse effects have been associated with the use of these agents and the liver is one of the organs most frequently involved. To provide a general overview of the potential impact of immune checkpoint inhibitors on the liver METHODS: We reviewed the literature and abstracts/presentations on immune checkpoint inhibitors at most relevant hepatology meetings over the last 5 years. The role of immune checkpoint inhibitors has been investigated both for the treatment of viral hepatitis and primary liver cancer. Hepatocellular carcinoma and chronic hepatitis B show the greatest potential for treatment with these drugs in the near future. However, immune-related adverse events involving the liver are a growing concern related to their widespread use. Immune checkpoint inhibitors represent an exciting new class of drugs with currently limited application in malignant and non-malignant liver disease. Caution must be exercised on the emergence of potentially severe immune adverse reactions.

References

Dec 22, 1998·The Journal of Experimental Medicine·A J ZajacR Ahmed
Sep 10, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Heiner WedemeyerBarbara Rehermann
Sep 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yoshiko IwaiNagahiro Minato
Jun 27, 2003·Proceedings of the National Academy of Sciences of the United States of America·Giao Q PhanSteven A Rosenberg
Sep 22, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hans Christian SpangenbergRobert Thimme
Feb 28, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Amalia PennaCarlo Ferrari
Apr 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jay H Hoofnagle
Feb 2, 2010·Pathologie-biologie·F V ChisariS F Wieland
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Mar 2, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Anna SchurichMala K Maini
May 11, 2011·The Journal of Clinical Investigation·Lukas BaitschDaniel E Speiser
May 16, 2012·Annals of Internal Medicine·Anna S F LokT Jake Liang
Aug 28, 2013·Proceedings of the National Academy of Sciences of the United States of America·Michael J FullerChristopher M Walker
Dec 23, 2014·Liver International : Official Journal of the International Association for the Study of the Liver·Carlo Ferrari
Aug 11, 2015·Nature Genetics·Hiromi NakamuraTatsuhiro Shibata
Sep 16, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J NaidooJ D Wolchok
Dec 31, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S ChampiatA Marabelle
Jan 15, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J M MichotO Lambotte
Nov 7, 2016·Journal of Hepatology·Austin G DuffyTim F Greten
Mar 7, 2017·International Journal of Cancer. Journal International Du Cancer·Wenjun WangJianxing He
Apr 22, 2017·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, UNKNOWN European Association for the Study of the Liver
Apr 28, 2017·Oncotarget·Jacqueline FontugneJulien Calderaro
Sep 20, 2017·Journal of Hepatology·Tim F Greten, Bruno Sangro
Sep 26, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A S KoksalE Parlak
Nov 23, 2017·Journal for Immunotherapy of Cancer·I PuzanovUNKNOWN Society for Immunotherapy of Cancer Toxicity Management Working Group
Jan 10, 2018·Frontiers in Immunology·Thomas C Wirth, Florian Kühnel
Jan 11, 2018·Gut and Liver·Antonio Bertoletti, Nina Le Bert
Feb 7, 2018·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Norah A TerraultJohn B Wong
Feb 15, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerUNKNOWN National Comprehensive Cancer Network
May 12, 2018·Journal of Hepatology·Marie-Léa GauciUNKNOWN PATIO group
Jun 2, 2018·The Oncologist·Kerry ReynoldsMichael Dougan

❮ Previous
Next ❯

Citations

Dec 11, 2020·The Cancer Journal·Mitchell S von ItzsteinDavid E Gerber
Mar 7, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Zhuoya WanQiang Ao
Sep 15, 2020·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Benoit GodbertPierre Gillet
Nov 19, 2020·JHEP Reports : Innovation in Hepatology·Eleonora De MartinDidier Samuel
Apr 8, 2021·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Neeraj Chhabra, Joseph Kennedy

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.